Search for a trial

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Primary Objective:• To compare the progression-free survival (PFS) of patients randomized to mirvetuximab soravtansine (MIRV) vs. Investigator*s choice of chemotherapy (IC Chemo) Key Secondary Objectives:• To compare the objective response rate (ORR…

Clinical outcome of routine treatment of patients with Pelvic Inflammatory Disease and/or Tubo Ovarial Abcess in the presence or absence of Mycoplasma genitalium (MG)

The primary aim of the present study is to investigate whether current standard treatment for PID is clinically effective in patients in whom Mycoplasma genitalium (MG) is present. A secondary aim of the study is to asses whether this treatment is…

An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (DCP-001) in high grade serous ovarian cancer patients after primary treatment

This study has been transitioned to CTIS with ID 2024-516781-10-00 check the CTIS register for the current data. Primary objective:• Systemic immunogenicity of the DCP-001 vaccination in high grade serous ovarian (HGSOC) cancer patients.